Lupin announced that its UK subsidiary, Lupin Healthcare (UK) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market Luforbec (beclometasone dipropionate/formoterol fumarate dihydrate) 100/6 µg pressurized metered-dose inhaler (pMDI), the first branded generic of Fostair(beclometasone dipropionate/formoterol fumarate dihydrate) 100/6 µg pMDI.
Luforbec 100/6 µg pMDI is indicated for regular treatment of asthma and for the symptomatic treatment of patients with severe chronic obstructive pulmonary disease (COPD) (FEV1 <50% predicted normal*).
In the twelve months to February 2021, the NHS spent over £179 million on Fostair100/6 µg pMDI and the availability of Luforbec 100/6 µg pMDI offers significant savings potential for the NHS, upon launch, informed a company statement.
Respiratory diseases affect one in five people. It is the third biggest cause of death in the UK and is a clinical priority for the NHS. In the UK, around 5.4 million people are currently receiving treatment for asthma, which is equivalent to one in every 12 adults. An estimated 1.2 million people are also living with COPD and this number is only set to increase. Asthma and COPD place a heavy cost burden on the NHS, estimated at £3 billion and £1.9 billion per year, respectively.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…